SCYNEXIS, Inc. (SCYX)

Market Cap	40.18M +2.7%
Revenue (ttm)	20.60M +449.9%
Net Income	-8.61M
EPS	-0.17
Shares Out	44.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	435,698
Open	0.8600
Previous Close	0.8600
Day's Range	0.8451 - 0.9300
52-Week Range	0.5650 - 1.3100
Beta	1.32
Analysts	Strong Buy
Price Target	3.00 (+233.52%)
Earnings Date	Mar 4, 2026

About SCYX

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: SCYX
• Website: https://www.scynexis.com

Financial Performance

In 2025, SCYNEXIS's revenue was $20.60 million, an increase of 449.95% compared to the previous year's $3.75 million. Losses were -$8.61 million, -59.56% less than in 2024.

Analyst Summary

According to one analyst, the rating for SCYX stock is "Strong Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(233.52% upside)

Analyst Consensus: Strong Buy